Transcriptomic analysis of tubular carcinomas of the breast reveals similarities and differences with molecular subtype-matched ductal and lobular carcinomas

Journal of Pathology

Volumn 222, Issue 1, 2010, Pages 64-75

  Lopez Garcia, Maria A ^a,b   Geyer, Felipe C ^a   Natrajan, Rachael ^a   Kreike, Bas ^c   Mackay, Alan ^a   Grigoriadis, Anita ^d   Reis Filho, Jorge S ^a   Weigelt, Britta ^e  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c Institute for Radiation Oncology Arnhem   (Netherlands)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Breast cancer; Histological grade; Invasive ductal carcinoma; Invasive lobular carcinoma; Microarrays; Molecular subtype; Tubular carcinoma

Indexed keywords

OLIGONUCLEOTIDE;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CELL CYCLE; CELL PROLIFERATION; CLUSTER ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRADUCTAL CARCINOMA; INVASIVE LOBULAR CARCINOMA; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTOMICS; TUBULAR CARCINOMA; VALIDATION PROCESS;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 77955482775     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2743     Document Type: Article

References (61)

1. Ellis P, Schnitt SJ, Sastre-Garau X, et al . Invasive breast carcinoma. In WHO Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs, Tavassoli FA, Devilee P (eds). Lyon Press: Lyon, 2003.
2. Rakha EA, Lee AH, Evans AJ, et al . Tubular carcinoma of the breast: further evidence to support its excellent prognosis. J Clin Oncol 2010; 28: 99-104.
3. Weigelt B, Reis-Filho JS. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nature Rev Clin Oncol 2009; 6: 718-730.
4. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Mol Oncol 2010; DOI:10.1016/j.molonc.2010.04.004.
5. Buerger H, Mommers EC, Littmann R, et al . Ductal invasive G2 and G3 carcinomas of the breast are the end stages of at least two different lines of genetic evolution. J Pathol 2001; 194: 165-170. (Pubitemid 32519965)
6. Ma XJ, Salunga R, Tuggle JT, et al . Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 2003; 100: 5974-5979.
7. Natrajan R, Lambros MB, Geyer FC, et al . Loss of 16q in high grade breast cancer is associated with estrogen receptor status: evidence for progression in tumors with a luminal phenotype? Genes Chromosomes Cancer 2009; 48: 351-365.
8. Natrajan R, Lambros MB, Rodriguez-Pinilla SM, et al . Tiling path genomic profiling of grade 3 invasive ductal breast cancers. Clin Cancer Res 2009; 15: 2711-2722.
9. Natrajan R, Weigelt B, Mackay A, et al . An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res Treat 2010; 121: 575-589.
10. Roylance R, Gorman P, Harris W, et al . Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. Cancer Res 1999; 59: 1433-1436.
11. Vincent-Salomon A, Lucchesi C, Gruel N, et al. Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res 2008; 14: 1956-1965.
12. Sotiriou C, Piccart MJ. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? Nature Rev Cancer 2007; 7: 545-553. (Pubitemid 46985399)
13. Sotiriou C, Wirapati P, Loi S, et al . Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006; 98: 262-272.
14. Cleton-Jansen AM, Buerger H, Haar N, et al . Different mechanisms of chromosome 16 loss of heterozygosity in well- versus poorly differentiated ductal breast cancer. Genes Chromosomes Cancer 2004; 41: 109-116.
15. Melchor L, Honrado E, Garcia MJ, et al . Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes. Oncogene 2008; 27: 3165-3175.
16. Simpson PT, Reis-Filho JS, Gale T, et al . Molecular evolution of breast cancer. J Pathol 2005; 205: 248-254.
17. Flagiello D, Gerbault-Seureau M, Sastre-Garau X, et al . Highly recurrent der(1;16)(q10;p10) and other 16q arm alterations in lobular breast cancer. Genes Chromosomes Cancer 1998; 23: 300-306.
18. Tsuda H, Takarabe T, Fukutomi T, et al . der(16)t(1;16)/der(1;16) in breast cancer detected by fluorescence in situ hybridization is an indicator of better patient prognosis. Genes Chromosomes Cancer 1999; 24: 72-77. (Pubitemid 28544465)
19. Buerger H, Otterbach F, Simon R, et al . Comparative genomic hybridization of ductal carcinoma in situ of the breast - evidence of multiple genetic pathways. J Pathol 1999; 187: 396-402.
20. Gao Y, Niu Y, Wang X, et al . Genetic changes at specific stages of breast cancer progression detected by comparative genomic hybridization. J Mol Med 2009; 87: 145-152.
21. Lu YJ, Osin P, Lakhani SR, et al . Comparative genomic hybridization analysis of lobular carcinoma in situ and atypical lobular hyperplasia and potential roles for gains and losses of genetic material in breast neoplasia. Cancer Res 1998; 58: 4721-4727.
22. Mastracci TL, Shadeo A, Colby SM, et al . Genomic alterations in lobular neoplasia: a microarray comparative genomic hybridization signature for early neoplastic proliferation in the breast. Genes Chromosomes Cancer 2006; 45: 1007-1017.
23. Simpson PT, Gale T, Reis-Filho JS, et al . Columnar cell lesions of the breast: the missing link in breast cancer progression? A morphological and molecular analysis. Am J Surg Pathol 2005; 29: 734-746.
24. Riener MO, Nikolopoulos E, Herr A, et al . Microarray comparative genomic hybridization analysis of tubular breast carcinoma shows recurrent loss of the CDH13 locus on 16q. Hum Pathol 2008; 39: 1621-1629.
25. Waldman FM, Hwang ES, Etzell J, et al . Genomic alterations in tubular breast carcinomas. Hum Pathol 2001; 32: 222-226. (Pubitemid 32193721)
26. Abdel-Fatah TM, Powe DG, Hodi Z, et al . High frequency of coexistence of columnar cell lesions, lobular neoplasia, and low grade ductal carcinoma in situ with invasive tubular carcinoma and invasive lobular carcinoma. Am J Surg Pathol 2007; 31: 417-426.
27. Abdel-Fatah TM, Powe DG, Hodi Z, et al . Morphologic and molecular evolutionary pathways of low nuclear grade invasive breast cancers and their putative precursor lesions: further evidence to support the concept of low nuclear grade breast neoplasia family. Am J Surg Pathol 2008; 32: 513-523.
28. Stalsberg H, Hartmann WH. The delimitation of tubular carcinoma of the breast. Hum Pathol 2000; 31: 601-607.
29. Goldstein NS, Kestin LL, Vicini FA. Refined morphologic criteria for tubular carcinoma to retain its favorable outcome status in contemporary breast carcinoma patients. Am J Clin Pathol 2004; 122: 728-739.
30. Cooper HS, Patchefsky AS, Krall RA. Tubular carcinoma of the breast. Cancer 1978; 42: 2334-2342.
31. Deos PH, Norris HJ. Well-differentiated (tubular) carcinoma of the breast. A clinicopathologic study of 145 pure and mixed cases. Am J Clin Pathol 1982; 78: 1-7.
32. Page DL. Special types of invasive breast cancer, with clinical implications. Am J Surg Pathol 2003; 27: 832-835.
33. Weigelt B, Horlings HM, Kreike B, et al . Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008; 216: 141-150.
34. Weigelt B, Geyer FC, Natrajan R, et al . The molecular underpinning of lobular histological growth pattern: a genome-wide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 2010; 220: 45-57.
35. Kreike B, Halfwerk H, Armstrong N, et al . Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 2009; 15: 4181-4190.
36. Kreike B, van Kouwenhove M, Horlings H, et al . Gene expression profiling and histopathological characterization of triplenegative/basal-like breast carcinomas. Breast Cancer Res 2007; 9: R65.
37. Parker JS, Mullins M, Cheang MC, et al . Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009; 27: 1160-1167.
38. Weigelt B, Mackay A, A'Hern R, et al . Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010; 11: 339-349.
39. Eisen MB, Spellman PT, Brown PO, et al . Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998; 95: 14863-14868.
40. Weigelt B, Geyer FC, Horlings HM, et al . Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type. Mod Pathol 2009; 22: 1401-1414.
41. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 5116-5121. (Pubitemid 32397092)
42. Nielsen TO, Hsu FD, Jensen K, et al . Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004; 10: 5367-5374.
43. Marchio C, Iravani M, Natrajan R, et al . Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 2008; 215: 398-410.
44. Wolff AC, Hammond ME, Schwartz JN, et al . American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
45. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
46. Arriola E, Marchio C, Tan DS, et al . Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Lab Invest 2008; 88: 491-503.
47. Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. Breast Cancer Res Treat 2009; 117: 273-280.
48. Gewinner C, Wang ZC, Richardson A, et al . Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009; 16: 115-125.
49. Sanghi S, Kumar R, Lumsden A, et al . cDNA and genomic cloning of lacritin, a novel secretion enhancing factor from the human lacrimal gland. J Mol Biol 2001; 310: 127-139. (Pubitemid 32619957)
50. Fritz BA, Poppel CS, Fei MW, et al . Processing of the major pancreatic zymogen granule membrane protein, GP2. Pancreas 2002; 24: 336-343.
51. Bertucci F, Orsetti B, Negre V, et al . Lobular and ductal carcinomas of the breast have distinct genomic and expression profiles. Oncogene 2008; 27: 5359-5372.
52. Korkola JE, DeVries S, Fridlyand J, et al . Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003; 63: 7167-7175.
53. Turashvili G, Bouchal J, Baumforth K, et al . Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007; 7: 55.
54. Zhao H, Langerod A, Ji Y, et al . Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 2004; 15: 2523-2536. (Pubitemid 38691844)
55. Hu Z, Fan C, Oh DS, et al . The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006; 7: 96.
56. Sorlie T, Tibshirani R, Parker J, et al . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003; 100: 8418-8423.
57. Girault I, Lerebours F, Amarir S, et al . Expression analysis of estrogen receptor alpha coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin Cancer Res 2003; 9: 1259-1266. (Pubitemid 36418375)
58. Kurebayashi J, Otsuki T, Kunisue H, et al . Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res 2000; 6: 512-518.
59. Lavinsky RM, Jepsen K, Heinzel T, et al . Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci U S A 1998; 95: 2920-2925.
60. Crowder RJ, Phommaly C, Tao Y, et al . PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res 2009; 69: 3955-3962.
61. Agarwal R, Gonzalez-Angulo AM, Myhre S, et al . Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res 2009; 15: 3654-3662.